ResearcherTexas A&M UniversityActive in the last 2 years

Havish Sairaju Kantheti

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-9077-6070; OpenAlex author ID A5080042973. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

Diagnostic and Prognostic Markers for Pancreatitis and Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms25126619 ↗
Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. Co-author DOI 10.1038/s41598-020-77373-8 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yalda Zolghadri · 2 shared papers, 2020–2024 · strength 0.26
- Paper Diagnostic and Prognostic Markers for Pancreatitis and Pancreatic Ductal Adenocarcinoma. DOI 10.3390/ijms25126619 ↗
- Paper Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. DOI 10.1038/s41598-020-77373-8 ↗
Huocong Huang · 2 shared papers, 2020–2024 · strength 0.26
- Paper Diagnostic and Prognostic Markers for Pancreatitis and Pancreatic Ductal Adenocarcinoma. DOI 10.3390/ijms25126619 ↗
- Paper Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. DOI 10.1038/s41598-020-77373-8 ↗
Raymond J. Macdonald · 2 shared papers, 2020–2024 · strength 0.26
- Paper Diagnostic and Prognostic Markers for Pancreatitis and Pancreatic Ductal Adenocarcinoma. DOI 10.3390/ijms25126619 ↗
- Paper Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. DOI 10.1038/s41598-020-77373-8 ↗
Thomas Martin Wilkie · 2 shared papers, 2020–2024 · strength 0.26
- Paper Diagnostic and Prognostic Markers for Pancreatitis and Pancreatic Ductal Adenocarcinoma. DOI 10.3390/ijms25126619 ↗
- Paper Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. DOI 10.1038/s41598-020-77373-8 ↗
Rolf A. Brekken · 2 shared papers, 2020–2024 · strength 0.26
- Paper Diagnostic and Prognostic Markers for Pancreatitis and Pancreatic Ductal Adenocarcinoma. DOI 10.3390/ijms25126619 ↗
- Paper Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. DOI 10.1038/s41598-020-77373-8 ↗
Giulio Innamorati · 1 shared paper, 2024 · strength 0.17
- Paper Diagnostic and Prognostic Markers for Pancreatitis and Pancreatic Ductal Adenocarcinoma. DOI 10.3390/ijms25126619 ↗
Ana Clara P. Azevedo‐Pouly · 1 shared paper, 2020 · strength 0.10
- Paper Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. DOI 10.1038/s41598-020-77373-8 ↗
Somayeh Layeghi‐Ghalehsoukhteh · 1 shared paper, 2020 · strength 0.10
- Paper Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. DOI 10.1038/s41598-020-77373-8 ↗
Ozhan Ocal · 1 shared paper, 2020 · strength 0.10
- Paper Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. DOI 10.1038/s41598-020-77373-8 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.